Phase II proof-of-concept trial of ruxolitinib in patients with non-small cell lung cancer.

Trial Profile

Phase II proof-of-concept trial of ruxolitinib in patients with non-small cell lung cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 11 Feb 2016 Based on the interim results of JANUS 1 and the phase 2 sub-study in patients with metastatic colorectal cancer and CRP, ongoing Incyte-sponsored trials of ruxolitinib in solid tumors will be discontinued, including the phase 3 JANUS 2 study in pancreatic cancer, the Phase 2 sub-study in patients with metastatic colorectal cancer and low CRP, and the phase 2 studies in breast and lung cancer, according to an Incyte Corporation media release.
    • 30 Oct 2014 Status changed from planning to recruiting, according to media release.
    • 27 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top